Revvity Cost of Goods Sold 2010-2024 | RVTY
Revvity annual/quarterly cost of goods sold history and growth rate from 2010 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
- Revvity cost of goods sold for the quarter ending December 31, 2024 was $0.317B, a 1.49% increase year-over-year.
- Revvity cost of goods sold for the twelve months ending December 31, 2024 was $1.217B, a 0.54% increase year-over-year.
- Revvity annual cost of goods sold for 2024 was $1.217B, a 0.54% increase from 2023.
- Revvity annual cost of goods sold for 2023 was $1.211B, a 8.4% decline from 2022.
- Revvity annual cost of goods sold for 2022 was $1.322B, a 5.15% decline from 2021.
| Revvity Annual Cost of Goods Sold (Millions of US $) |
|
|---|---|
| 2024 | $1,217 |
| 2023 | $1,211 |
| 2022 | $1,322 |
| 2021 | $1,394 |
| 2020 | $933 |
| 2019 | $1,488 |
| 2018 | $1,437 |
| 2017 | $1,183 |
| 2016 | $1,101 |
| 2015 | $1,141 |
| 2014 | $1,135 |
| 2013 | $1,181 |
| 2012 | $1,144 |
| 2011 | $1,071 |
| 2010 | $943 |
| 2009 | $850 |
| Revvity Quarterly Cost of Goods Sold (Millions of US $) |
|
|---|---|
| 2024-12-31 | $317 |
| 2024-09-30 | $299 |
| 2024-06-30 | $306 |
| 2024-03-31 | $295 |
| 2023-12-31 | $312 |
| 2023-09-30 | $298 |
| 2023-06-30 | $307 |
| 2023-03-31 | $293 |
| 2022-12-31 | $305 |
| 2022-09-30 | $305 |
| 2022-06-30 | $344 |
| 2022-03-31 | $368 |
| 2021-12-31 | $-10 |
| 2021-09-30 | $338 |
| 2021-06-30 | $543 |
| 2021-03-31 | $523 |
| 2020-12-31 | $-212 |
| 2020-09-30 | $437 |
| 2020-06-30 | $364 |
| 2020-03-31 | $344 |
| 2019-12-31 | $407 |
| 2019-09-30 | $365 |
| 2019-06-30 | $375 |
| 2019-03-31 | $341 |
| 2018-12-31 | $380 |
| 2018-09-30 | $342 |
| 2018-06-30 | $363 |
| 2018-03-31 | $352 |
| 2017-12-31 | $334 |
| 2017-09-30 | $285 |
| 2017-06-30 | $289 |
| 2017-03-31 | $274 |
| 2016-12-31 | $290 |
| 2016-09-30 | $266 |
| 2016-06-30 | $283 |
| 2016-03-31 | $263 |
| 2015-12-31 | $229 |
| 2015-09-30 | $309 |
| 2015-06-30 | $311 |
| 2015-03-31 | $292 |
| 2014-12-31 | $233 |
| 2014-09-30 | $299 |
| 2014-06-30 | $308 |
| 2014-03-31 | $295 |
| 2013-12-31 | $313 |
| 2013-09-30 | $289 |
| 2013-06-30 | $299 |
| 2013-03-31 | $280 |
| 2012-12-31 | $303 |
| 2012-09-30 | $279 |
| 2012-06-30 | $283 |
| 2012-03-31 | $279 |
| 2011-12-31 | $300 |
| 2011-09-30 | $254 |
| 2011-06-30 | $270 |
| 2011-03-31 | $247 |
| 2010-12-31 | $259 |
| 2010-09-30 | $233 |
| 2010-06-30 | $232 |
| 2010-03-31 | $218 |
| 2009-12-31 | $144 |
| 2009-09-30 | $208 |
| 2009-06-30 | $250 |
| 2009-03-31 | $247 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $13.985B | $2.755B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $150.904B | 28.19 |
| Elevance Health (ELV) | United States | $87.590B | 11.69 |
| CVS Health (CVS) | United States | $79.455B | 11.63 |
| Cencora (COR) | United States | $47.362B | 17.19 |
| DiDi Global (DIDIY) | China | $23.670B | 0.00 |
| Natera (NTRA) | United States | $20.908B | 0.00 |
| ICON (ICLR) | Ireland | $16.429B | 14.61 |
| BioMerieux (BMXMF) | France | $13.758B | 0.00 |
| Viatris (VTRS) | United States | $13.595B | 4.19 |
| Doximity (DOCS) | United States | $13.537B | 70.40 |
| Solventum (SOLV) | United States | $13.178B | 0.00 |
| Avantor (AVTR) | United States | $11.895B | 17.47 |
| CochLear (CHEOY) | Australia | $11.072B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.491B | 27.26 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $9.952B | 0.00 |
| HealthEquity (HQY) | United States | $9.484B | 47.58 |
| Charles River Laboratories (CRL) | United States | $8.719B | 16.52 |
| Sonic Healthcare (SKHHY) | Australia | $8.501B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $6.224B | 31.72 |
| Bausch + Lomb (BLCO) | Canada | $5.573B | 25.50 |
| Organon (OGN) | United States | $3.884B | 3.96 |
| Sotera Health (SHC) | United States | $3.814B | 20.40 |
| BrightSpring Health Services (BTSG) | United States | $3.382B | 71.93 |
| Surgery Partners (SGRY) | United States | $3.198B | 36.46 |
| Concentras Parent (CON) | United States | $2.951B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.613B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.610B | 316.67 |
| Ardent Health Partners (ARDT) | United States | $2.014B | 0.00 |
| PACS (PACS) | United States | $1.980B | 0.00 |
| Progyny (PGNY) | United States | $1.961B | 39.71 |
| Teladoc Health (TDOC) | United States | $1.961B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.845B | 48.40 |
| Premier (PINC) | United States | $1.690B | 10.82 |
| Agilon Health (AGL) | United States | $1.500B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.409B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.346B | 11.28 |
| CareDx (CDNA) | United States | $1.146B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $1.026B | 8.12 |
| Establishment Labs Holdings (ESTA) | $0.986B | 0.00 | |
| Embecta (EMBC) | United States | $0.798B | 5.47 |
| Auna S.A (AUNA) | Luxembourg | $0.598B | 0.00 |
| SBC Medicals (SBC) | United States | $0.484B | 0.00 |
| MultiPlan (MPLN) | United States | $0.472B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.472B | 0.00 |
| DocGo (DCGO) | United States | $0.453B | 17.08 |
| InnovAge Holding (INNV) | United States | $0.449B | 0.00 |
| Enhabit (EHAB) | United States | $0.406B | 35.09 |
| QDM (QDMI) | Hong Kong, SAR China | $0.335B | 8.78 |
| Nutex Health (NUTX) | United States | $0.314B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.253B | 0.00 |
| LifeMD (LFMD) | United States | $0.248B | 0.00 |
| Beauty Health (SKIN) | United States | $0.194B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.193B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.140B | 0.00 |
| Biodesix (BDSX) | United States | $0.122B | 0.00 |
| So-Young (SY) | China | $0.116B | 19.63 |
| Ascend Wellness Holdings (AAWH) | United States | $0.086B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.078B | 0.00 |
| ModivCare (MODV) | United States | $0.071B | 3.85 |
| Oncology Institute (TOI) | United States | $0.064B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 1.61 |
| OncoCyte (OCX) | United States | $0.046B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.035B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.020B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.015B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.014B | 0.00 |
| KindlyMD (KDLY) | United States | $0.013B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.007B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |